Completed trials
Host Defence Peptides
Technology
Completed trials
Posters
Publications
Pipeline
Completed clincal trials:
- A first in man Phase I study to investigate tolerability and safety of topical LTX-109 in healthy subjects (Study C08-109-01)
- A Phase I/IIa study to evaluate the safety, tolerability and efficacy of topical LTX-109 in subjects nasally colonized with methicillin-resistant/-sensitive Staphylococcus aureus (MRSA/MSSA; Study C10-109-02)
https://clinicaltrials.gov/ct2/show/NCT01158235?cond=LTX-109&draw=2&rank=6
- A Phase II, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of two doses of LTX-109 (1 % and 2 %) versus placebo in impetigo (Study C12-109-04)
https://clinicaltrials.gov/ct2/show/NCT01803035?cond=LTX-109&draw=2&rank=3
- A Phase IIa pilot study to evaluate the safety, tolerability and efficacy of LTX-109 in patients with uncomplicated, Gram-positive, skin infection (Study C10-109-03)
https://clinicaltrials.gov/ct2/show/NCT01223222?cond=LTX-109&draw=2&rank=5
Impetigo
Nasal Decolonization
Overview of completed studies
